Abstract library

57 results for "PanNETassigner subtype".
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#1584 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: An Analysis of 241 Cases
Introduction: Definition of type 3 gastric NEN in 2012 and 2016 ENETS guidelines is not clear, so Four-type classification has been proposed.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Prof. Huang-Ying Tan
Authors: Tan H Y, Dou D, Zhang P, Zhang C, ...
Keywords: gastric nen, subtype
#2125 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: 400 Cases of Multicenter Retrospective Analysis
Introduction: Definitions of Type 3 gastric NEN (g-NEN) in ENETS Guidelines 2012 and 2016 are ambiguous and controversial, so Four-type classification has been proposed in China.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Zhang P, Qiu X D, Li X K, ...
#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
#302 Monoclonal Antibodies Against the Human Somatostatin Receptor Subtypes 1-5: Characterization and Immunohistochemical Application in Gastrointestinal Neuroendocrine Tumors
Introduction: A lack of well-characterized somatostatin receptor (sstr)-specific antibodies has hampered development of routine sstr expression profiles that may be useful in the treatment of NET patients (pts).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Chiara Lambertini
#446 Comparative Expression Analysis of Somatostatin Receptor Subtypes in Human Neuroendocrine Tumors Using Two Sets of New Monoclonal Antibodies
Introduction: Expression of somatostatin receptor subtypes (sstr) is required for the successful use of somatostatin analogues (SSA) in the treatment of neuroendocrine tumors (NET). Reliable detection of sstr could improve the selection of SSA treatment. Rabbit and mouse monoclonal antibodies (mAbs) were recently developed independently in Jena and Basel.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Herbert Schmid
#1070 Subtype Classification and Clinicopathological Characteristics of 78 Cases with Gastric Neuroendocrine Neoplasms
Introduction: Gastric NENs are a group of neoplasms with diverse clinicopathological features.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang C, Tan H Y, Liu J X, Luo J, ...
#36 A monocentric analysis of patients with pulmonary neuroendocrine tumors over 15 years: long term survival and life quality dependent from histological subtypes and surgical management
Introduction: Pulmonary neuroendocrine tumors substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized interdisciplinary centers, a broad therapeutical armentarium can be used to achieve optimal treatment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof. Johannes N Hoffmann
Authors: Zahn S, Hornung H, Schick K S, Winter H, ...
#1287 Subtype Classification and Clinicopathological Features of Gastric Neuroendocrine Neoplasms: Experiences in 116 Chinese Patients
Introduction: Gastric NEN are a heterogeneous group of tumors.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Zhang P, Zhang C, Luo J, Liu J X, ...
Keywords: gastric nen, type 1
#791 Quantification of Somatostatin Receptor Subtypes Using In Vivo PET/CT-Data, Ex Vivo Conventional Immunohistochemistry and Automated Digitized Analysis by Definiens XD Image Software
Introduction: Diagnostics and therapy of NET are significantly influenced by their somatostatin receptor (SSTR) status. Immunohistochemistry (IHC) of SSTR performed by pathologists is a time-consuming and cost-intensive procedure.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: Dr. med. Daniel Kaemmerer
Keywords: SSTR